These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 27461444)

  • 1. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy versus conventionally fractionated external beam radiotherapy for low- and intermediate-risk prostate cancer.
    Lee SH; Kim HJ; Kim WC
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):388-395. PubMed ID: 27461444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancer.
    Phak JH; Kim HJ; Kim WC
    Prostate Int; 2016 Mar; 4(1):25-9. PubMed ID: 27014661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir.
    Anwar M; Weinberg V; Chang AJ; Hsu IC; Roach M; Gottschalk A
    Radiat Oncol; 2014 Feb; 9():42. PubMed ID: 24484652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost and whole pelvic radiotherapy for intermediate- and high-risk prostate cancer.
    Kim HJ; Phak JH; Kim WC
    Asia Pac J Clin Oncol; 2017 Feb; 13(1):21-27. PubMed ID: 26969216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results and PSA kinetics after robotic SBRT for prostate cancer: multicenter retrospective study in Korea (Korean radiation oncology group study 15-01).
    Park Y; Park HJ; Jang WI; Jeong BK; Kim HJ; Chang AR
    Radiat Oncol; 2018 Nov; 13(1):230. PubMed ID: 30470253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.
    Jabbari S; Weinberg VK; Kaprealian T; Hsu IC; Ma L; Chuang C; Descovich M; Shiao S; Shinohara K; Roach M; Gottschalk AR
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):228-34. PubMed ID: 21183287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen kinetics after stereotactic body radiotherapy as monotherapy or boost after whole pelvic radiotherapy for localized prostate cancer.
    Kim HJ; Phak JH; Kim WC
    Prostate Int; 2015 Dec; 3(4):118-22. PubMed ID: 26779457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate specific antigen kinetics following robotic stereotactic body radiotherapy for localized prostate cancer.
    Kole TP; Chen LN; Obayomi-Davies O; Kim JS; Lei S; Suy S; Dritschilo A; Collins SP
    Acta Oncol; 2015 Jun; 54(6):832-8. PubMed ID: 25467965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate- and high-risk prostate cancer.
    Kim HJ; Phak JH; Kim WC
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e342-e347. PubMed ID: 26846353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conventionally Fractionationed Volumetric Arc Therapy versus Hypofractionated Stereotactic Body Radiotherapy: Quality of Life, Side Effects, and Prostate-Specific Antigen Kinetics in Localized Prostate Cancer.
    Tambas M; Agaoglu F; Iribas A; Guveli M; Dizdar Y; Okutan M; Sahin D; Tenekeci N; Darendeliler E
    Value Health Reg Issues; 2016 Sep; 10():91-99. PubMed ID: 27881285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Dose Robotic Stereotactic Body Radiotherapy in the Treatment of Patients With Prostate Cancer: Preliminary Results in 26 Patients.
    Pontoriero A; Iatì G; Mondello S; Midili F; Siragusa C; Brogna A; Ielo I; Anastasi G; Magno C; Pergolizzi S; De Renzis C
    Technol Cancer Res Treat; 2016 Feb; 15(1):179-85. PubMed ID: 25586517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic body radiotherapy as boost for organ-confined prostate cancer.
    Katz AJ; Santoro M; Ashley R; Diblasio F; Witten M
    Technol Cancer Res Treat; 2010 Dec; 9(6):575-82. PubMed ID: 21070079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific Antigen Bounce After Stereotactic Body Radiotherapy for Prostate Cancer: A Pooled Analysis of Four Prospective Trials.
    Roy S; Loblaw A; Cheung P; Chu W; Chung HT; Vesprini D; Ong A; Chowdhury A; Panjwani D; Pang G; Korol R; Davidson M; Ravi A; McCurdy B; Helou J; Zhang L; Mamedov A; Deabreu A; Quon HC
    Clin Oncol (R Coll Radiol); 2019 Sep; 31(9):621-629. PubMed ID: 31126725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes.
    Zelefsky MJ; Gomez DR; Polkinghorn WR; Pei X; Kollmeier M
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):529-33. PubMed ID: 23523323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early and multiple PSA bounces can occur following high-dose prostate stereotactic body radiation therapy: Subset analysis of a phase 1/2 trial.
    Kim DN; Straka C; Cho LC; Lotan Y; Yan J; Kavanagh B; Raben D; Cooley S; Brindle J; Xie XJ; Pistenmaa D; Timmerman R
    Pract Radiat Oncol; 2017; 7(1):e43-e49. PubMed ID: 27637137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease control outcomes of stereotactic body radiation therapy or moderate hypo-fractionation for prostate cancer: Real-world experience at two Canadian centers.
    Hu HP; Anagnostopoulos G; Gouran-Savadkoohi M; Dayes I; Ishkanian A; Hallock A; Lukka H; Quan K; Schnarr K; Cuthbert D; Goldberg M; Chang YM; Tsakiridis T
    Prostate; 2024 Feb; 84(2):193-202. PubMed ID: 37880911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients.
    Levin-Epstein R; Cook RR; Wong JK; Stock RG; Jeffrey Demanes D; Collins SP; Aghdam N; Suy S; Mantz C; Katz AJ; Nickols NG; Miszczyk L; Napieralska A; Namysl-Kaletka A; Prionas ND; Bagshaw H; Buyyounouski MK; Cao M; Mahal BA; Shabsovich D; Dang A; Yuan Y; Rettig MB; Chang AJ; Jackson WC; Spratt DE; Lehrer EJ; Zaorsky NG; Kupelian PA; Steinberg ML; Horwitz EM; Jiang NY; Kishan AU
    Radiother Oncol; 2020 Oct; 151():26-32. PubMed ID: 32663537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control.
    Levin-Epstein RG; Jiang NY; Wang X; Upadhyaya SK; Collins SP; Suy S; Aghdam N; Mantz C; Katz AJ; Miszczyk L; Napieralska A; Namysl-Kaletka A; Prionas N; Bagshaw H; Buyyounouski MK; Cao M; Agazaryan N; Dang A; Yuan Y; Kupelian PA; Zaorsky NG; Spratt DE; Mohamad O; Feng FY; Mahal BA; Boutros PC; Kishan AU; Juarez J; Shabsovich D; Jiang T; Kahlon S; Patel A; Patel J; Nickols NG; Steinberg ML; Fuller DB; Kishan AU
    Radiother Oncol; 2021 Jan; 154():207-213. PubMed ID: 33035622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.
    Chen LN; Suy S; Uhm S; Oermann EK; Ju AW; Chen V; Hanscom HN; Laing S; Kim JS; Lei S; Batipps GP; Kowalczyk K; Bandi G; Pahira J; McGeagh KG; Collins BT; Krishnan P; Dawson NA; Taylor KL; Dritschilo A; Lynch JH; Collins SP
    Radiat Oncol; 2013 Mar; 8():58. PubMed ID: 23497695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.